In Brief: Columbia Labs' Crinone
Executive Summary
Columbia Labs' Crinone: NDA filed for the vaginally-delivered natural progesterone gel for use in advanced reproductive technologies procedures, the company announces Nov. 13. Columbia states that Phase III studies of the gel showed pregnancy rates of approximately 50%. The Miami-based women's pharmaceutical company previously filed an NDA for Crinone in July, seeking approval for hormonal therapy in patients with secondary amenorrhea...